MarketPR
New penile length data from the Level 1 CAPTAIN randomized controlled trial put PROF in focus Friday, with Profound Medical Corp.
(NASDAQ: PROF; TSX: PRN) reporting no median change in penile length at one month after the TULSA Procedure, against a median 0.65 cm reduction following robotic radical prostatectomy.
The between-arm difference, estimated at 0.42 cm via mixed-effects model, cleared statistical significance at p<0.001.
The three-year primary efficacy endpoint, which tracks freedom from additional prostate cancer treatment and prostate cancer-related death, is the next definitive read for the setup.
Keep reading